HopeStage
Back to all studies
CompletedNCT01172652

Ziprasidone for Anxiety Symptoms in People Living With Bipolarity

About this title

Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder(GAD)

Read the official source — NCT01172652
Medication studyAges 18–65United States
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 65 years.

Listed locations
Palo Alto and 2 more locationsSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateApril 2010
Recruitment status
Completed
Enrollment listed in the registry
49
Sponsor
VA Palo Alto Health Care System
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT01172652
Official title
Show the full official title

A Randomized, Double-Blind, Placebo-Controlled Study of Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Palo Alto · Tampa · Mason

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is VA Palo Alto Health Care System.

Did this study involve medication?

Yes. The study involved medication, including Ziprasidone and Placebo.

Who was this study for?

Listed age limits: 18 years to 65 years.

Want to explore more studies?

Explore studies